CA3012404A1 - Means and methods for staging, typing and treating a cancerous disease - Google Patents
Means and methods for staging, typing and treating a cancerous disease Download PDFInfo
- Publication number
- CA3012404A1 CA3012404A1 CA3012404A CA3012404A CA3012404A1 CA 3012404 A1 CA3012404 A1 CA 3012404A1 CA 3012404 A CA3012404 A CA 3012404A CA 3012404 A CA3012404 A CA 3012404A CA 3012404 A1 CA3012404 A1 CA 3012404A1
- Authority
- CA
- Canada
- Prior art keywords
- dcc
- cells
- somatic
- cancer
- dccs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152883.1A EP3199641B1 (en) | 2016-01-27 | 2016-01-27 | Means and methods for staging, typing and treating a cancerous disease |
| EP16152883.1 | 2016-01-27 | ||
| PCT/EP2017/051789 WO2017129753A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3012404A1 true CA3012404A1 (en) | 2017-08-03 |
Family
ID=55310656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3012404A Pending CA3012404A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11702701B2 (enExample) |
| EP (2) | EP3199641B1 (enExample) |
| JP (1) | JP2019508032A (enExample) |
| KR (1) | KR20180102674A (enExample) |
| CN (1) | CN108770360B (enExample) |
| AU (1) | AU2017211976B2 (enExample) |
| CA (1) | CA3012404A1 (enExample) |
| ES (1) | ES2905208T3 (enExample) |
| SG (1) | SG11201805990XA (enExample) |
| WO (1) | WO2017129753A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673541B1 (en) | 1998-09-18 | 2004-01-06 | Micromet Ag | DNA amplification of a single cell |
| WO2002037113A2 (en) * | 2000-11-03 | 2002-05-10 | Michael Giesing | Clinical and functional validation of targets from disseminated cancer cells |
| ITRM20110149A1 (it) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione. |
| WO2013009632A2 (en) * | 2011-07-08 | 2013-01-17 | The University Of Utah Research Foundation | Methods of detecting hereditary cancer predisposition |
| EP3211099A1 (en) * | 2011-12-10 | 2017-08-30 | Abbott Molecular Inc. | Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma |
| WO2015023551A1 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
| US10273538B2 (en) | 2014-02-05 | 2019-04-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Error-free sequencing of DNA |
-
2016
- 2016-01-27 ES ES16152883T patent/ES2905208T3/es active Active
- 2016-01-27 EP EP16152883.1A patent/EP3199641B1/en active Active
-
2017
- 2017-01-27 AU AU2017211976A patent/AU2017211976B2/en active Active
- 2017-01-27 SG SG11201805990XA patent/SG11201805990XA/en unknown
- 2017-01-27 KR KR1020187024606A patent/KR20180102674A/ko active Pending
- 2017-01-27 EP EP17706412.8A patent/EP3408411A1/en not_active Withdrawn
- 2017-01-27 JP JP2018539138A patent/JP2019508032A/ja active Pending
- 2017-01-27 US US16/073,271 patent/US11702701B2/en active Active
- 2017-01-27 WO PCT/EP2017/051789 patent/WO2017129753A1/en not_active Ceased
- 2017-01-27 CN CN201780008861.6A patent/CN108770360B/zh active Active
- 2017-01-27 CA CA3012404A patent/CA3012404A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017211976B2 (en) | 2022-09-22 |
| US11702701B2 (en) | 2023-07-18 |
| JP2019508032A (ja) | 2019-03-28 |
| AU2017211976A1 (en) | 2018-08-02 |
| CN108770360A (zh) | 2018-11-06 |
| EP3199641B1 (en) | 2021-09-29 |
| KR20180102674A (ko) | 2018-09-17 |
| CN108770360B (zh) | 2022-06-14 |
| WO2017129753A8 (en) | 2017-10-19 |
| EP3199641A1 (en) | 2017-08-02 |
| WO2017129753A1 (en) | 2017-08-03 |
| ES2905208T3 (es) | 2022-04-07 |
| SG11201805990XA (en) | 2018-08-30 |
| US20190062845A1 (en) | 2019-02-28 |
| EP3408411A1 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Radke et al. | The genomic and transcriptional landscape of primary central nervous system lymphoma | |
| Guo et al. | DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs | |
| US20220010385A1 (en) | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors | |
| Perrone et al. | PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | |
| Staudt et al. | The biology of human lymphoid malignancies revealed by gene expression profiling | |
| Hodgkinson et al. | Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer | |
| Rahrmann et al. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis | |
| Ren et al. | Gene expression predicts dormant metastatic breast cancer cell phenotype | |
| Lorenzo-Martín et al. | VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma | |
| Zhai et al. | Arid1a inactivation in an Apc‐and Pten‐defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival | |
| Vincenzo et al. | Application of molecular biology of differentiated thyroid cancer for clinical prognostication | |
| Guijarro et al. | Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling | |
| Gulati et al. | Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma | |
| Mellai et al. | Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas | |
| US11702701B2 (en) | Means and methods for staging, typing and treating a cancerous disease | |
| Gimeno-Valiente et al. | DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution | |
| Powers et al. | The molecular pathology of sarcomas | |
| Ghatalia et al. | Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma | |
| Repo et al. | Functional assay for assessment of pathogenicity of BAP1 variants | |
| Gürgen et al. | A molecularly characterized preclinical platform of subcutaneous renal cell carcinoma (RCC) patient-derived xenograft models to evaluate novel treatment strategies | |
| Park et al. | High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis | |
| CN110684843B (zh) | 罹癌个体样本中生物标记的用途 | |
| Fadl et al. | Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation | |
| Cramer et al. | Forward genetic screening in engineered colorectal cancer organoids identifies novel regulators of metastasis | |
| Jacobi et al. | EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |